Senti Biosciences(US:SNTI)2025-03-20 20:21Financial Performance - Senti Bio reported a net loss of $0.6 million, or $0.67 per share, for Q4 2024, compared to a net loss of $18.7 million, or $4.19 per share, in Q4 2023[11]. - Research and development expenses decreased to $7.8 million in Q4 2024 from $9.1 million in Q4 2023, while total operating expenses for the year were $61.0 million, down from $95.3 million in 2023[11][15]. - The total stockholders' equity decreased to $25.6 million as of December 31, 2024, down from $66.9 million in 2023[14]. Cash and Funding - The company raised gross proceeds of approximately $47.6 million from PIPE financing, which is expected to extend its financial runway into 2026[5]. - As of December 31, 2024, Senti Bio held cash and cash equivalents of $48.3 million, an increase from $35.9 million in 2023[14]. - The company received an additional $1.5 million from its $8 million grant from the California Institute for Regenerative Medicines, bringing the total received to $6.4 million[6][7]. - Senti Bio plans to use the net proceeds of $45.1 million from PIPE financing to fund the continued development of the SENTI-202 program and other R&D activities[5]. Clinical Trials - Initial data from the SENTI-202 clinical trial showed that 2 out of 3 AML patients achieved complete remission, with both being MRD negative[4][10]. Leadership Changes - The company expanded its senior leadership team with the appointment of Jay Cross as CFO and Faraz Siddiqui as SVP of Technical Operations[7]. Operating Expenses - General and administrative expenses for Q4 2024 were $8.4 million, down from $9.3 million in Q4 2023[11][15].